ResMed stock holds above $240 as latest earnings beat expectations
Published on 08/29/2026 at 20:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (ISIN AU000000RMD6) stock is trading above $240 following its latest quarterly report, which showed earnings and revenue ahead of expectations as of August 28, 2026. The medical equipment and cloud-connected health company also lifted its quarterly dividend, underscoring management confidence in cash generation.
Per recent market data, ResMed stock opened at $240.47 in the most recent session, with the shares described as trading up 2.0 percent versus the prior close. This price level sits almost exactly in line with the average analyst price target of $239.38, signaling that the stock is already valued close to consensus expectations. A separate S&P 500 component overview shows the shares quoted at $240.31 with a 1.89 percent daily gain on August 28, 2026, highlighting that ResMed participated in the broader index moves on that date. The FX-based technical snapshot for the ticker RMD reported a closing price of $240.33 on August 28, 2026, with a daily increase of 1.94 percent, confirming the upward move in the latest completed trading session.
Latest earnings beat and revenue growth
In its most recent quarterly earnings release, ResMed reported earnings per share of $2.95 for the period, surpassing the consensus estimate of $2.89 by $0.06 in that quarter. This modest but clear beat suggests that the company managed to deliver slightly better profitability than analysts had anticipated. During the same quarter of the previous year, ResMed had reported earnings per share of $2.55, so the latest figure represents an increase of $0.40 year over year, which is a sizable improvement for a mature medical-technology business.
On the top line, ResMed generated quarterly revenue of $1.46 billion, matching the consensus revenue estimate of $1.46 billion for the period. While the company did not exceed revenue expectations in absolute terms, the reported figure still represents healthy growth compared with the same quarter a year earlier. The business recorded an 8.6 percent year-over-year increase in revenue, demonstrating that demand for its devices and software platforms continues to expand at a mid-single- to high-single-digit pace. For investors, that 8.6 percent growth rate matters because it pairs with margin resilience, meaning ResMed is not sacrificing profitability simply to chase sales.
Profitability metrics in the quarter underline that point. ResMed achieved a net margin of 26.94 percent, indicating that more than one quarter of every dollar of revenue fell to the bottom line after all expenses. Return on equity came in at 25.58 percent, a strong figure that signals efficient use of shareholder capital. Together, these metrics paint a picture of a business that generates robust cash flows and retains pricing power, even as competition in the sleep-disordered breathing and chronic respiratory care markets remains intense.
Dividend increase and full-year outlook
The latest corporate actions also reflect ongoing confidence in cash generation. ResMed recently declared a quarterly dividend of $0.66 per share, to be paid to shareholders of record on August 20, 2026, with payment scheduled for September 24, 2026. This new dividend level represents an increase from the prior quarterly dividend of $0.60 per share, raising the annualized payout from $2.40 to $2.64 per share. On the basis of the recent $240.47 share price, this equates to a forward dividend yield of approximately 1.1 percent, which is modest but meaningful for a growth-oriented health technology company.
The company’s dividend payout ratio stands at 25.31 percent, meaning that just over one quarter of earnings are being returned directly to shareholders in cash. That ratio leaves significant room for continued investment in research and development, manufacturing capacity and cloud-based software platforms while still offering a growing cash return to investors. The pattern of increasing the quarterly dividend from $0.60 to $0.66 per share suggests a deliberate approach to balancing shareholder returns with the funding needs of the business.
On the earnings outlook, sell-side analysts collectively forecast that ResMed will deliver 12.03 earnings per share for the current fiscal year, according to the latest aggregated research overview. When compared to the most recent quarterly EPS of $2.95, this full-year expectation implies that analysts anticipate steady performance over the remaining quarters, with some room for seasonal variation. The current forecast also reflects confidence that ResMed can maintain its profitability metrics while continuing to grow revenue in the mid-single- to high-single-digit range.
Analyst view and valuation context
Analysts are generally cautious on ResMed, with the stock carrying a consensus rating classified as hold across recent research summaries. Seven analysts currently assign the shares a buy rating, while ten rate them as hold, indicating a mixed but not bearish stance. The average price target of $239.38 sits just below the recent opening price of $240.47, reinforcing the view that ResMed stock is trading very close to what the analyst community considers fair value on a one-year horizon.
For investors, the narrow gap between the current share price and the consensus target means that much of the positive earnings news may already be reflected in valuation. The latest quarter’s 8.6 percent revenue growth and EPS beat of $0.06 versus expectations are encouraging, but they have not yet driven analysts to push targets significantly higher across the board. Some firms have recently reaffirmed neutral or hold ratings and made incremental adjustments to their price targets, indicating a view that upside will depend on continued execution rather than a single transformative catalyst.
Despite that caution, the repeated confirmation of strong return on equity at 25.58 percent and net margin of 26.94 percent provides a counterweight. Those metrics indicate that ResMed remains an efficient and profitable business, which can justify a premium valuation compared with less profitable peers in medical technology and digital health. If the company can sustain revenue growth in the high-single-digit range while keeping margins stable, there is scope for the stock to re-rate higher over time, even if the current consensus remains anchored near the present price.
Market performance and S&P 500 footing
Recent trading data place ResMed firmly within the broader US equity landscape. An S&P 500 component overview lists ResMed shares with a latest price of 240.31, a daily change of 1.89 percent on August 28, 2026, and a one-day performance reflective of resilience relative to major indices that closed lower at the end of that trading session. That profile highlights how ResMed stock can move independently from broader index swings, driven by company-specific factors such as earnings and dividend decisions.
In the same data section, ResMed’s market capitalization is indicated in the tens of billions of US dollars, underscoring its status as a large-cap health technology company. The S&P 500 membership also means that the stock is held by a wide range of institutional investors, including index funds and sector-focused strategies. Recent filings show institutional ownership at 54.98 percent of the outstanding shares, indicating that more than half of the company’s equity is controlled by professional investors and funds.
The share’s recent move higher, with a closing price of $240.33 on August 28, 2026 and a daily gain just under 2 percent, arrived despite reports that major US stock indices closed lower that day. This divergence suggests that company-specific news, particularly the earnings beat and dividend increase, provided support for ResMed even as the broader market faced pressure. For investors, such behavior is valuable because it shows the stock can act as a partial counterbalance within diversified portfolios when index moves are negative.
Sleep apnea devices and cloud-connected solutions
ResMed’s core business centers on devices and digital platforms designed to diagnose, treat and monitor sleep-disordered breathing and chronic respiratory conditions. The company is widely known for its continuous positive airway pressure (CPAP) and bilevel devices that help patients with obstructive sleep apnea maintain airflow during sleep. These devices are complemented by masks, accessories and patient monitoring tools that form an integrated system for home and clinical use.
Over recent years, ResMed has invested heavily in cloud-based connectivity, integrating its devices with software platforms that can collect usage data, compliance metrics and therapy effectiveness indicators. These platforms give clinicians and home-care providers real-time insights into patient adherence, allowing them to adjust settings or provide additional support when needed. For patients, app-based interfaces can offer feedback on sleep quality, reminders to use therapy and educational materials to improve engagement.
The company also serves segments beyond sleep apnea. It provides ventilators and respiratory support devices for patients with chronic obstructive pulmonary disease and other respiratory disorders, as well as solutions for in-hospital and home-care environments. This broader portfolio helps diversify revenue sources and reduces reliance on any single therapy area, which can be important when regulatory or reimbursement changes affect particular product categories.
Investor implications of the latest quarter
Investors evaluating ResMed after the latest quarter can draw several conclusions from the numbers. First, the EPS beat of $0.06 against consensus, combined with revenue growth of 8.6 percent, demonstrates that the company continues to deliver incremental outperformance rather than experiencing sudden slowdowns. The year-over-year EPS increase from $2.55 to $2.95 is meaningful in percentage terms, reflecting both volume growth and operational efficiency.
Second, the dividend increase from $0.60 to $0.66 per share per quarter signals management confidence. Raising the annualized payout to $2.64 while maintaining a payout ratio of 25.31 percent indicates that ResMed sees its earnings power as durable enough to support higher cash distributions without compromising investment capacity. For income-focused investors, the combination of a 1.1 percent yield and growth in the underlying distribution can be attractive in the context of a health technology name.
Third, the valuation context, with the stock trading at $240.47 versus an average target of $239.38, implies that the market is pricing ResMed in line with the analyst consensus. That leaves limited margin of safety for investors seeking discount entries but also shows that there is no obvious overvaluation signal embedded in the latest data. The hold-skewed rating distribution means that many analysts are waiting for further evidence of sustained growth or new product catalysts before revising targets significantly higher.
ResMed shares on the ASX and global footprint
ResMed is listed on the New York Stock Exchange under the ticker RMD, but the company also has a presence on the Australian Securities Exchange via a secondary listing. One recent snapshot shows the ASX RMD line trading at A$31.72 on August 17, 2026, with a small daily decline of A$0.31, equating to a 0.968 percent move. That Australian quote gives local investors a way to participate in ResMed’s global growth story through a home-market listing, and it highlights the geographic breadth of the shareholder base.
The dual listing structure supports liquidity and visibility across regions, aligning with ResMed’s corporate roots and research operations in both the United States and Australia. For investors who focus on currency exposure, the presence of both USD and AUD-denominated lines can offer strategic choices depending on whether they prefer US dollar assets or Australian dollar assets in their portfolios.
Key metrics to watch ahead
Looking ahead, several metrics from the latest quarter will be important for tracking ResMed’s trajectory. Revenue growth around the 8.6 percent mark needs to be sustained or improved to justify the current valuation and support upward revisions in analyst targets. If subsequent quarters show acceleration toward double-digit growth, the case for re-rating the stock may strengthen, especially given the already strong margin profile.
Margin trends will also remain central. Net margin at 26.94 percent and return on equity at 25.58 percent are high-quality figures for a device and software hybrid business. Any indication that these metrics are under pressure, whether from reimbursement changes, competition or input-cost inflation, could affect investor appetite. Conversely, stability or improvement in margins would reinforce the narrative of ResMed as a durable, high-return compounder.
On capital allocation, continued dividend growth and the possibility of share repurchases will be watched closely. The increase in the quarterly dividend to $0.66 per share, yielding 1.1 percent annually at recent prices, sets expectations that ResMed will continue to reward shareholders directly. If earnings grow in line with the forecast of 12.03 EPS for the current year, there could be room for further payout increases without jeopardizing investment in new technologies.
Product innovation and digital health positioning
Beyond the headline numbers, ResMed’s strategic positioning in digital health is a key element of the investment case. Its cloud-connected devices and software platforms place the company at the intersection of medical technology and data-driven care. By collecting and analyzing patient data from CPAP and respiratory devices, ResMed can contribute to better adherence, improved outcomes and more efficient resource use in healthcare systems.
This data-centric approach also opens avenues for new business models, such as subscription-based software access for providers or analytics services that help payers manage populations with sleep apnea and chronic respiratory conditions. As healthcare systems increasingly focus on value-based care and outcomes, companies that can provide both hardware and actionable data are positioned to benefit.
ResMed’s emphasis on user-friendly interfaces and interoperability with electronic health record systems supports adoption among clinicians and providers. While the latest quarter’s financials highlight the success of existing products, the long-term thesis relies on the company’s ability to continue innovating in device design, software features and data analytics to maintain a competitive edge.
ResMed’s flagship sleep therapy systems
At the product level, a flagship example of ResMed’s technology is its family of sleep therapy systems that integrate CPAP devices, masks and cloud-backed monitoring. These systems are designed to deliver precise airflow tailored to individual patient needs, helping to prevent airway collapse during sleep for those with obstructive sleep apnea. The devices work together with mobile apps and web portals that allow patients to track their nightly usage and quality of sleep in a simple, intuitive format.
Clinicians use the associated software platforms to monitor adherence, adjust pressure settings and intervene early when patients struggle with therapy. By combining high-quality hardware with responsive software tools, ResMed aims to reduce discontinuation rates and improve long-term outcomes, which in turn supports reimbursement and provider relationships. The commercial success of these systems contributes meaningfully to the company’s revenue base and underpins the strong margins reported in the latest quarter.
ResMed stock and current price context
As of the latest completed trading session on August 28, 2026, ResMed stock closed at $240.33 in New York, reflecting a 1.94 percent gain on the day and an opening level around $240.47 in subsequent trading. That price situates the shares slightly above the consensus analyst target of $239.38, reinforcing the idea that current valuation already discounts much of the positive earnings and dividend news. For investors, the key question is whether ongoing revenue growth, margin strength and product innovation will justify higher targets and support further upside over time.
Given the company’s role in treating sleep-disordered breathing and chronic respiratory conditions, as well as its strong presence in digital health, ResMed remains a central player in an important healthcare niche. The latest numbers show a business that continues to grow and generate high returns, while the dividend increase provides an additional return channel for shareholders. With ResMed stock trading close to analyst fair value estimates and delivering an annualized dividend of $2.64 per share, future performance will depend on the company’s ability to sustain and build on its current trajectory.
Read more
Recent institutional investment and earnings details for ResMed
ResMed sleep therapy systems
ResMed’s integrated sleep therapy systems combine advanced CPAP devices, comfortable masks and cloud-linked software to help patients manage obstructive sleep apnea at home while giving clinicians detailed data to fine-tune treatment plans.
ResMed stock price and listing
ResMed stock is listed on the New York Stock Exchange under the ticker RMD, and as of August 28, 2026, the shares closed at $240.33 in US trading, supported by strong quarterly earnings, solid revenue growth and an increased dividend.
Fact box
Company: ResMed Inc.
ISIN: AU000000RMD6
Ticker: RMD
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 4:00 p.m. ET): $240.33 USD
Market cap: $34.54 billion (as of August 28, 2026)
Sector / Industry: Health care - Medical devices and digital health
Index membership: S&P 500
